Moneycontrol PRO

Hold Sanofi India; target of Rs 6885: ICICI Direct

ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6885 in its research report dated July 27, 2022.

July 29, 2022 / 06:57 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct's research report on Sanofi India


Sanofi offers drugs in therapies like diabetes (insulins & orals), cardiology, pain, allergy and epilepsy. Around 70% of sales stem from top 7 brands. Lantus, Allegra & Combiflam are in Top 100 pharmaceutical brands in India • Sanofi enjoys strong brand recall in anti-diabetic therapy in India.


Outlook


We maintain HOLD rating on the stock due to lack of visible growth triggers and ramp up in ex-power brand portfolio. Valued at Rs6885 i.e. 26x P/E on FY24E EPS on Rs 264.8.


For all recommendations report, click here

Close

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Sanofi India - 280722 - icici

Broker Research
first published: Jul 29, 2022 06:57 pm
Sections
ISO 27001 - BSI Assurance Mark